Earlier this week, Abbott received U.S. FDA clearance and CE Mark for Ultreon 3.0, an AI-powered optical coherence tomography ...

Abbott (NYSE:ABT) announced today that it received FDA clearance and CE mark for its next-generation Ultreon 3.0 software.

Abbott Laboratories (NYSE:ABT) is one of the best medical device stocks to invest in right now. Abbott Laboratories (NYSE:ABT ...

Abbott receives US FDA clearance and CE Mark for next-generation Ultreon 3.0 AI-powered coronary imaging platform: Abbott Park, Illinois Thursday, April 30, 2026, 14:00 Hrs [IST] ...

A decade after predictions that AI would make radiologists obsolete, demand and salaries for the profession have risen sharply, fueled by growing imaging needs and new AI tools that assist rather than ...

The device joins a portfolio of vascular technologies that generated 9.5% sales growth on a comparable basis in the first ...

To better equip doctors with critical information related to blood clots in patients, Abbott created the Ultreon 1.0 Software, the first of its kind. The Ultreon 1.0 Software gives doctors enhanced ...

Sharjah: Al Qassimi Hospital in Sharjah, part of Emirates Health Services (EHS), has announced the launch of the latest coronary angiography programme, Ultreon 3.0, a fourth‑generation, ...

CHENNAI: Kauvery Heart Institute, the centre of excellence in comprehensive cardiac services at Kauvery Hospital – Kovilambakkam, announces the launch of the latest AI-based Ultreon Coronary Imaging ...

Abbott has received both FDA clearance and CE mark for its Ultreon 3.0 software, an AI-powered optical coherence tomography platform for coronary imaging. The system provides real-time guidance during ...

Abbott (NYSE: ABT) today announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software. This marks a major step forward as it brings ...